GT200500235A - Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos - Google Patents

Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos

Info

Publication number
GT200500235A
GT200500235A GT200500235A GT200500235A GT200500235A GT 200500235 A GT200500235 A GT 200500235A GT 200500235 A GT200500235 A GT 200500235A GT 200500235 A GT200500235 A GT 200500235A GT 200500235 A GT200500235 A GT 200500235A
Authority
GT
Guatemala
Prior art keywords
glicerol
growth hormone
human growth
ramified
polyethylenglycol
Prior art date
Application number
GT200500235A
Other languages
English (en)
Spanish (es)
Inventor
Rory Francis Finn
Ned Roger Siegel
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200500235(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of GT200500235A publication Critical patent/GT200500235A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GT200500235A 2004-08-31 2005-08-30 Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos GT200500235A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31

Publications (1)

Publication Number Publication Date
GT200500235A true GT200500235A (es) 2006-03-21

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500235A GT200500235A (es) 2004-08-31 2005-08-30 Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos

Country Status (24)

Country Link
EP (1) EP1789092A2 (ru)
JP (1) JP2008511610A (ru)
KR (1) KR20070042567A (ru)
CN (1) CN101010105A (ru)
AP (1) AP2007003919A0 (ru)
AR (1) AR050851A1 (ru)
AU (1) AU2005278903A1 (ru)
BR (1) BRPI0515118A (ru)
CA (1) CA2577999A1 (ru)
CR (1) CR8942A (ru)
EA (1) EA200700380A1 (ru)
EC (1) ECSP077281A (ru)
GT (1) GT200500235A (ru)
IL (1) IL181085A0 (ru)
MA (1) MA28908B1 (ru)
MX (1) MX2007002441A (ru)
NL (1) NL1029828C2 (ru)
NO (1) NO20071322L (ru)
PE (1) PE20060654A1 (ru)
TN (1) TNSN07078A1 (ru)
TW (1) TW200621291A (ru)
UY (1) UY29088A1 (ru)
WO (1) WO2006024953A2 (ru)
ZA (1) ZA200701802B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69838552T2 (de) 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
EP2305804B1 (en) 1999-01-14 2015-05-06 Bolder Biotechnology, Inc. MonoPEGylated human growth hormone
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
US20090117077A1 (en) * 2006-05-12 2009-05-07 Dong-A Pharm. Co., Ltd. Polyethylene glycol-interferon alpha conjugate
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
KR101079993B1 (ko) * 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
EP2300501B1 (en) * 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
EA020347B1 (ru) 2008-07-31 2014-10-30 Фармаиссэншиа Корп. Пептид-полимерные конъюгаты
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
WO2010040187A1 (en) 2008-10-10 2010-04-15 The Bionic Ear Institute Polymer-bioactive agent conjugates
EP2355853B1 (en) * 2008-10-10 2016-12-07 Polyactiva Pty Ltd Biodegradable polymer - bioactive moiety conjugates
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
BR122021021381B1 (pt) 2009-02-03 2023-05-16 Amunix Pharmaceuticals, Inc Método de aprimoramento de uma propriedade de uma proteína biologicamente ativa
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
CN101831067A (zh) * 2010-05-31 2010-09-15 王二新 聚乙二醇脂类缀合物及其在制备药物中的应用
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (zh) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 链官能化的多级支化聚乙二醇及其合成方法
WO2014110867A1 (zh) * 2013-01-17 2014-07-24 厦门赛诺邦格生物科技有限公司 一种单一官能化的支化聚乙二醇及其修饰的生物相关物质
CN104877127B (zh) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
MY191506A (en) 2014-11-06 2022-06-28 Pharmaessentia Corp Dosage regimen for pegylated interferon
US11518781B2 (en) 2017-12-29 2022-12-06 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
US20200362002A1 (en) * 2017-12-29 2020-11-19 Hoffmann-La Roche Inc. Process for providing pegylated protein composition
US20200323993A1 (en) * 2017-12-29 2020-10-15 Hoffmann-La Roche Inc. Process for providing pegylated protein composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (ja) * 1996-11-05 2000-09-25 日本油脂株式会社 コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
JP3921781B2 (ja) * 1998-02-12 2007-05-30 日本油脂株式会社 カルボキシル基含有ポリオキシアルキレン化合物
EP2305804B1 (en) * 1999-01-14 2015-05-06 Bolder Biotechnology, Inc. MonoPEGylated human growth hormone
HUP0500997A2 (en) * 2001-11-20 2007-11-28 Pharmacia Corp Chemically-modified human growth hormone conjugates
ES2897470T3 (es) * 2002-09-09 2022-03-01 Nektar Therapeutics Alcanales poliméricos solubles en agua
JP4412461B2 (ja) * 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
EP1581260B1 (en) * 2002-12-31 2014-09-17 Nektar Therapeutics Polymeric reagents comprising a ketone or a related functional group
WO2005000360A2 (en) * 2003-05-23 2005-01-06 Nektar Therapeutics Al, Corporation Peg derivatives having an amidocarbonate linkage

Also Published As

Publication number Publication date
TNSN07078A1 (fr) 2008-06-02
CN101010105A (zh) 2007-08-01
ECSP077281A (es) 2007-03-29
MA28908B1 (fr) 2007-10-01
AP2007003919A0 (en) 2007-02-28
IL181085A0 (en) 2007-07-04
MX2007002441A (es) 2007-05-04
CA2577999A1 (en) 2006-03-09
TW200621291A (en) 2006-07-01
EP1789092A2 (en) 2007-05-30
UY29088A1 (es) 2006-03-31
NL1029828A1 (nl) 2006-03-01
CR8942A (es) 2007-08-16
ZA200701802B (en) 2008-08-27
WO2006024953A2 (en) 2006-03-09
JP2008511610A (ja) 2008-04-17
NO20071322L (no) 2007-05-29
BRPI0515118A (pt) 2008-07-01
AU2005278903A1 (en) 2006-03-09
AR050851A1 (es) 2006-11-29
NL1029828C2 (nl) 2006-10-20
KR20070042567A (ko) 2007-04-23
PE20060654A1 (es) 2006-08-12
WO2006024953A3 (en) 2007-01-18
EA200700380A1 (ru) 2007-10-26

Similar Documents

Publication Publication Date Title
GT200500235A (es) Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparacion y metodos de uso de los mismos
AR047928A1 (es) Derivados de tetrahidropiridoindol
GT200500237A (es) Derivados de pirimidina
CL2007001166A1 (es) Compuestos derivados de pirimidina condensada, inhibidores de pi3-quinasa; procesos para preparar los compuestos; composicion farmaceutica que los comprende; uso de los compuestos en la preparacion de medicamentos; proceso para preparar la composicion farmaceutica; y kit que incluye a la composicion farmaceutica
ECSP066856A (es) Compuestos novedosos como moduladores del receptor opioide
NI201000193A (es) Formulaciones orales de análogos de citidina y métodos de uso de las mismas.
ECSP10010684A (es) Agonistas mezclados, basados en gip para el tratamiento de trastornos metabólicos y obesidad.
CL2011002430A1 (es) Variante de peptido natriuretico de tipo c (cnp); composicion farmaceutica que la comprende; metodo de produccion, celula huesped y uso de dicha variante.
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
UY29002A1 (es) Nuevos derivados de hidantoína, procesos parasu preparación, composiciones farmacéuticas que los contienen y su uso en terapia
UY27720A1 (es) Aroilpiridinonas monocíclicas,
ECSP055699A (es) Indazoles, benzotiazoles y benzoisotiazoles, y su preparacion y usos
GT200600258A (es) Derivados de n-(piridin-2-il)-sulfonamida
ECSP067093A (es) Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
PA8638801A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
PA8638701A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
CR20110579A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
CO6280470A2 (es) Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina
WO2007059979A3 (en) Allergy treatment by epicutaneous allergen administration
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
UY31922A (es) Compuestos
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.